A RANDOMIZED, PHASE I/II TRIAL TO ASSESS THE SAFETY AND ANTIVIRAL EFFECTS OF ESCALATING DOSES OF A HUMAN ANTI-CYTOMEGALOVIRUS MONOCLONAL ANTIBODY (SDZ MSL-109) IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND CMV VIREMIA AND/OR VIRURIA: